All In Biotech

Investigational drug · Phase 2

EO2463

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Follicular Lymphoma, Marginal Zone Lymphoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "EO2463"

First trial start

2021

Jul 5, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "EO2463", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Follicular Lymphoma
  • Marginal Zone Lymphoma

Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "EO2463" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Follicular Lymphoma

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • CC-99282BMS-986369, GolcadomidePhase 37 trials

    Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma

  • MK-1045CN-201Phase 36 trials

    Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular

  • NemtabrutinibMK-1026, ARQ 531Phase 36 trials

    Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma

  • TacabrutidegBGB-16673Phase 36 trials

    BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma

  • AbexinostatPCI-24781Phase 35 trials

    Xynomic Pharmaceuticals, Inc. · Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma

  • TQB2825Phase 33 trials

    Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Diffuse Large Cell B-lymphoma

  • Zugocabtagene geleucelCTX112Phase 23 trials

    CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.